Nat Cancer

Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Tamborero D, Dienstmann R, Rachid MH, ..., Rodon J, Lehtiö J

Nat Cancer 3 (5) 649 [2022-05-00; online 2022-04-23]

Global Proteomics and Proteogenomics [Technology development]

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Tamborero D, Dienstmann R, Rachid MH, ..., Rodon J, Lehtiö J

Nat Cancer 3 (2) 251-261 [2022-02-00; online 2022-02-24]

Global Proteomics and Proteogenomics [Technology development]

Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress.

Bonagas N, Gustafsson NMS, Henriksson M, ..., Homan EJ, Helleday T

Nat Cancer 3 (2) 156-172 [2022-02-00; online 2022-02-28]

Drug Discovery and Development (DDD) [Collaborative]

Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms.

Lehtiö J, Arslan T, Siavelis I, ..., Staaf J, Orre LM

Nat Cancer 2 (11) 1224-1242 [2021-11-00; online 2021-11-22]

Global Proteomics and Proteogenomics [Technology development]

The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome.

Duran-Ferrer M, Clot G, Nadeu F, ..., Campo E, Martín-Subero JI

Nat Cancer 1 (11) 1066-1081 [2020-11-00; online 2020-11-02]

NGI SNP genotyping [Collaborative] NGI Uppsala (SNP&SEQ Technology Platform) [Collaborative] National Genomics Infrastructure [Collaborative]